FreeOx Biotech
Advancing Stroke Care through Innovation and Precision Medicine.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | €1.5m | Seed | |
| Total Funding | 000k | ||
| EUR | 2021 | 2022 |
|---|---|---|
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
Related Content
FreeOx Biotech is a pioneering late-stage clinical biotechnology company dedicated to transforming Acute Ischemic Stroke (AIS) management. Our mission is to improve outcomes for stroke patients through the discovery and development of Cerebrovascular Protective Therapeutics.
Our lead asset, Ox-01, is a Phase 3-ready investigational drug with breakthrough potential as an emergency adjunct therapy to Mechanical Thrombectomy. Selected by the prestigious StrokeNet Thrombectomy Endovascular Platform (STEP) program, funded by the National Institute of Neurological Disorders and Stroke (NINDS), Ox-01 represents a paradigm shift in AIS treatment.
As we approach the initiation of our pivotal trials in Q1 2026, we are currently engaged in critical regulatory discussions with the FDA to ensure compliance and readiness. Concurrently, manufacturing of Ox-01 is underway to meet trial demands. Additionally, our intellectual property strategy has been strengthened by the recent filing of a composition of matter patent for Ox-01, securing its unique therapeutic profile.
Backed by strong scientific evidence and a commitment to innovation, FreeOx Biotech is at the forefront of addressing one of the most critical unmet needs in cerebrovascular care.